4 results
Primary Objective * To demonstrate the efficacy of tofactitinib in inducing remission in subjects with moderately to severely active UC. Secondary Objectives * To evaluate the safety and tolerability of tofactitinib in subjects with moderately to…
The primary study objective is to determine whether Febuxostat daily 80-120 mg is better than Allopurinol daily 100-600 mg in inducing positive changes in Pulse Wave Velocity (PWV) after 36 weeks of treatment.
The GO TEST OVERTURE study aims to demonstrate the superiority of the Treat to Target management strategy over a Treat to Avoid Symptoms approach in terms of clinical remission of gout symptoms.
To test whether the proportion of patients in remission during the last 6 months of follow up is higher for a T2T strategy compared to a T2S stop strategy.